Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05227118
PHASE1

Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.

Official title: A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK-8189 in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis

Key Details

Gender

All

Age Range

65 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

29

Start Date

2022-07-01

Completion Date

2023-01-10

Last Updated

2026-04-29

Healthy Volunteers

No

Interventions

DRUG

Elpipodect

MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths

DRUG

Placebo

MK-8189 matching placebo administered orally QD

Locations (8)

CITrials ( Site 0007)

Santa Ana, California, United States

Top Medical Research ( Site 0005)

Cutler Bay, Florida, United States

Velocity Clinical Research, Hallandale Beach ( Site 0001)

Hallandale, Florida, United States

Well Pharma Medical Research, Corp. ( Site 0006)

Miami, Florida, United States

Atlanta Center for Medical Research ( Site 0004)

Atlanta, Georgia, United States

iResearch Atlanta ( Site 0009)

Decatur, Georgia, United States

Global Medical Institutes LLC; Princeton Medical Institute ( Site 0008)

Princeton, New Jersey, United States

Richmond Behavioral Associates ( Site 0003)

Staten Island, New York, United States